All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma

June 18th 2025

The FDA approved tafasitamab-cxix plus lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma.

Long-Term Data Support Venetoclax Plus Rituximab in Relapsed/Refractory CLL

June 18th 2025

Venetoclax plus rituximab displayed OS and PFS benefits vs BR after long-term follow-up in relapsed/refractory CLL.

Zanubrutinib/Venetoclax Yields Deep Responses in Treatment-Naive CLL Regardless of Del17p/TP53 Mutational Status

June 18th 2025

Mazyar Shadman, MD, MPH, discusses key efficacy and safety findings from arm D of the SEQUOIA trial of first-line zanubrutinib plus venetoclax in CLL/SLL.

FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML and Hematologic Malignancies

June 18th 2025

SENTI-202 receives FDA orphan drug designation for treating relapsed/refractory hematologic malignancies, including AML.

Atebimetinib Plus Chemo Displays Potential Survival Benefit in First-Line Pancreatic Cancer

June 18th 2025

Atebimetinib plus gemcitabine/nab-paclitaxel produced signals of survival benefits in first-line pancreatic cancer.

Real-World Analysis Suggests Social Determinants of Health May Be Associated With Early Onset of CRC

June 18th 2025

Jessica Paulus, ScD, highlights factors that may contribute to the increasing incidence of colorectal cancer in patients younger than 50 years of age.

Hematologists Highlight Notable Insights From the 2025 EHA Congress

June 18th 2025

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

Intentional Treatment Sequencing Strategies Optimize SCLC and NSCLC Management

June 18th 2025

Miguel Gonzalez-Velez, MD, discusses the clinical implications of several lung cancer trials that were presented at the 2025 ASCO Annual Meeting.

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS

June 17th 2025

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.

FDA Declines to Expand Label for Talazoparib/Enzalutamide in mCRPC

June 17th 2025

The FDA declined to expand the label for talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer.

Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia

June 17th 2025

Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.

Could Electric Fields Supercharge Immune Attack on the Deadliest Form of Brain Cancer?

June 17th 2025

Electric field device placed on the scalp, along with immunotherapy and chemotherapy may help patients with glioblastoma live longer, particularly those with large, inoperable tumors.

Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL

June 17th 2025

Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.

Health Canada Approves Quizartinib Plus Chemotherapy for Newly Diagnosed FLT3-ITD+ AML

June 17th 2025

Health Canada has approved a quizartinib-based regimen for the treatment of patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

VERONA Trial Misses Primary End Point of OS Benefit With Azacitidine/Venetoclax in Higher-Risk MDS

June 17th 2025

Venetoclax plus azacitidine did not yield an OS benefit vs placebo plus azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes.

LUMINOSITY Data Continue to Highlight Utility of Telisotuzumab Vedotin in c-MET–Overexpressing NSCLC

June 17th 2025

Jonathan Goldman, MD, discusses the role of telisotuzumab vedotin in c-MET–overexpressing, nonsquamous, EGFR wild-type advanced NSCLC.

Ibrutinib Plus Venetoclax and A CD20 Monoclonal Antibody Increases MRD Negativity in Untreated MCL

June 17th 2025

Treatment with ibrutinib plus venetoclax and a CD20 monoclonal antibody induced high MRD negativity rates vs ibrutinib/anti-CD20 in untreated MCL.

Retifanlimab Presents a New Treatment Option for Locally Recurrent or Metastatic SCAC

June 17th 2025

Cathy Eng, MD, FACP, FASCO, highlights the significance of the FDA approval of retifanlimab for managing locally recurrent or metastatic SCAC.

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL

June 16th 2025

PROs were improved with pirtobrutinib among evaluable patient with CLL/SLL treated during the BRUIN CLL-321 trial.

Roswell Park Quick Talks: Breast Cancer and ADCs, Risk of Second HPV-Related Cancer, Cognitive Function and ICIs

June 16th 2025

Experts from Roswell Park shared findings on these topics at the 2025 ASCO Annual Meeting.